The ongoing pilot study (N=30) has enrolled 15 moderate to severe dry eye patients in an open label, single arm study. It included a single treatment in one eye and a follow-up period of 3 months, in which safety and efficacy endpoints are evaluated.
Study sites are Hadassah Ein Karem and Shaare Zedek medical centers in Jerusalem, IL, and Wolfson Medical center in Holon, IL.